Compare FBYD & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBYD | CCCC |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | 207 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.8M | 185.1M |
| IPO Year | N/A | 2020 |
| Metric | FBYD | CCCC |
|---|---|---|
| Price | $11.28 | $2.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 108.9K | ★ 2.1M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $268.88 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $3.71 | $1.09 |
| 52 Week High | $29.02 | $3.82 |
| Indicator | FBYD | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 61.15 | 55.49 |
| Support Level | $10.27 | $2.26 |
| Resistance Level | $13.05 | $2.85 |
| Average True Range (ATR) | 1.81 | 0.20 |
| MACD | 0.57 | -0.02 |
| Stochastic Oscillator | 53.39 | 89.57 |
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.